Loading...
TTALO logo
TTALO
Terveystalo Oyj

Earnings Will Grow Faster In 2025 With Improved Margin Outlook

Published
03 Aug 25
Updated
09 Dec 25
Views
32
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-8.6%
7D
2.6%

Author's Valuation

€11.316.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Narrative
Updates4

Shared on 09 Dec 25

TTALO: Expanded Diagnostics Partnership And Earnings Outlook Will Support Upside Into 2025

Analysts have nudged their price target for Terveystalo Oyj to EUR 11.30, reflecting largely unchanged assumptions on discount rate, revenue growth, profit margins, and future valuation multiples that continue to support a steady, fairly valued outlook. What's in the News Terveystalo and Nightingale Health signed a new agreement that deepens their strategic partnership and extends Nightingale's blood analysis service to all Terveystalo customer segments, beyond its existing use in occupational health checks for over 200,000 Finns (Key Developments) The expanded Nightingale collaboration aims to advance innovative healthcare by using a single blood sample to provide disease risk assessments for multiple chronic diseases, now integrated more broadly into Terveystalo's service offering (Key Developments) Terveystalo reaffirmed its earnings guidance for 2025, stating that it expects earnings per share to grow on average by 10 percent per year, with faster EPS growth in 2025 as fewer items affecting comparability are anticipated (Key Developments) Valuation Changes Fair Value: unchanged at €11.30 per share, indicating no reassessment of the company’s intrinsic value.
Read more

Shared on 24 Nov 25

TTALO: Earnings Guidance Consistency Will Support Upside Momentum Into 2025

Read more

Shared on 07 Nov 25

Fair value Decreased 5.64%

TTALO: Earnings Guidance Will Drive Share Price Higher In 2025

Read more

Shared on 24 Oct 25

Fair value Decreased 4.96%
Read more